Status:
COMPLETED
P4 (Pregabalin for Peripheral Posttraumatic Pain)
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Neuralgia
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
To evaluate the efficacy of pregabalin compared to placebo in the treatment of posttraumatic peripheral neuropathic pain
Eligibility Criteria
Inclusion
- Diagnosis of Posttraumatic Peripheral Neuropathic Pain (NeP) syndrome, including post-surgical NeP, NeP due to peripheral nerve injury, and phantom limb pain, confirmed by a qualified pain specialist and persisting for a minimum of 3 months following the traumatic event
Exclusion
- Subjects whose posttraumatic neuropathic pain is due to Complex Regional Pain Syndrome (CRPS, Type I or Type II)
- NeP not due to trauma, and not peripheral pain
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
255 Patients enrolled
Trial Details
Trial ID
NCT00292188
Start Date
January 1 2006
End Date
May 1 2008
Last Update
February 9 2021
Active Locations (44)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Brussels, Belgium, 1070
2
Pfizer Investigational Site
Genk, Belgium, B-3600
3
Pfizer Investigational Site
Liège, Belgium, 4020
4
Pfizer Investigational Site
Liège, Belgium, B-4000